(Q36363225)

13 August 2017

title

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers (English)

1 reference

13 August 2017

1 reference

Tomonori Habuchi

1

1 reference

13 August 2017

Michael Marberger

2

1 reference

13 August 2017

Michael J Droller

3

1 reference

13 August 2017

George P Hemstreet

4

1 reference

13 August 2017

H Barton Grossman

5

1 reference

13 August 2017

Jack A Schalken

6

1 reference

13 August 2017

Bernd J Schmitz-Dräger

7

1 reference

13 August 2017

William M Murphy

8

1 reference

13 August 2017

Aldo V Bono

9

1 reference

13 August 2017

Peter Goebell

10

1 reference

13 August 2017

Robert H Getzenberg

11

1 reference

13 August 2017

Stefan H Hautmann

12

1 reference

13 August 2017

Edward Messing

13

1 reference

13 August 2017

Yves Fradet

14

1 reference

13 August 2017

Vinata B Lokeshwar

15

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

66

1 reference

13 August 2017

issue

6 Suppl 1

1 reference

13 August 2017

page(s)

64-74

1 reference

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: an alternative to classic prognostic indicators?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

What we could do now: molecular pathology of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Original Articles: Bladder Cancer: Long-Term Outcome Related to Epidermal Growth Factor Receptor Status in Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Use of Immunohistochemically Demonstrated c-erb B-2 Oncoprotein Expression as a Prognostic Factor in Transitional Cell Carcinoma of the Urinary Bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Evaluation of c-ras oncogene product (p21) in superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Expression of ras p21 oncogene product on human bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Altered patterns of MDM2 and TP53 expression in human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Detection of the c-myc gene product in urinary bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

c-myc in bladder cancer. Clinical findings and analysis of mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

p53 mutations in human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Accumulation of nuclear p53 and tumor progression in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

p53 Expression Predicts Progression and Poor Survival in T1 Bladder Tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

The prognostic value of p53 in superficially infiltrating transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

p53 and treatment of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

p53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Altered Expression of Retinoblastoma Protein and Known Prognostic Variables in Locally Advanced Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Expression of p21(waf1/cip1) protein in transitional cell bladder tumours and its prognostic value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Glutathione S-transferase and multidrug-resistant phenotype in transitional cell carcinoma of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Expression of MDR-1 Gene in Transitional Cell Carcinoma and its Correlation with Chemotherapy Response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.065

10.1016/J.UROLOGY.2005.08.065

7 January 2021

Identifiers

DOI

1 reference

13 August 2017

1 reference